These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 24879927)

  • 1. Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.
    Sisley S; Smith K; Sandoval DA; Seeley RJ
    Peptides; 2014 Aug; 58():1-6. PubMed ID: 24879927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
    Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
    Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
    Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
    Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
    McKay NJ; Kanoski SE; Hayes MR; Daniels D
    Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
    Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
    Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.
    Barrera JG; D'Alessio DA; Drucker DJ; Woods SC; Seeley RJ
    Diabetes; 2009 Dec; 58(12):2820-7. PubMed ID: 19741167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.
    Burmeister MA; Ayala J; Drucker DJ; Ayala JE
    Am J Physiol Endocrinol Metab; 2013 Apr; 304(7):E677-85. PubMed ID: 23341495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
    Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
    J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
    Irwin N; Flatt PR; Patterson S; Green BD
    Eur J Pharmacol; 2010 Feb; 628(1-3):268-73. PubMed ID: 19917278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice.
    Burmeister MA; Ayala JE; Smouse H; Landivar-Rocha A; Brown JD; Drucker DJ; Stoffers DA; Sandoval DA; Seeley RJ; Ayala JE
    Diabetes; 2017 Feb; 66(2):372-384. PubMed ID: 27908915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
    Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R
    Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.
    Dalvi PS; Nazarians-Armavil A; Purser MJ; Belsham DD
    Endocrinology; 2012 May; 153(5):2208-22. PubMed ID: 22334721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.
    Anderberg RH; Richard JE; Eerola K; López-Ferreras L; Banke E; Hansson C; Nissbrandt H; Berqquist F; Gribble FM; Reimann F; Wernstedt Asterholm I; Lamy CM; Skibicka KP
    Diabetes; 2017 Apr; 66(4):1062-1073. PubMed ID: 28057699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.